SABER® Platform

SABER = Sucrose acetate isobutyrate extended release

Components

Active pharmaceutical ingredient (API)

  • Novel or established agent
  • Small-molecule structure

SAIB (sucrose acetate isobutyrate)

  • Esterified sugar derivative
  • Biocompatible, biodegradable, water-insoluble matrix
  • Traps API at high concentrations

Solvent

  • Optimizes viscosity for injection through small-gauge needle
  • Diffuses rapidly, leaving in situ drug depot

Learn more about SABER-based pipeline products:

POSIMIR® (bupivacaine extended-release solution)

SABER Publications
  • Wright JC, Matriano J. Long acting injections and implants. In: Hillery AM, Park K, eds. Drug Delivery: Fundamentals & Applications. 2nd ed. Boca Raton, FL: CRC Press; 2016:137-170.
  • Wright JC, Verity AN, Okumu FW. The SABER™ delivery system for parenteral administration. In: Rathbone MJ, Hadgraft J, Roberts MS, Lane ME, eds. Modified-Release Drug Delivery Technology. Vol 2. 2nd ed. Boca Raton, FL: CRC Press; 2013:151-158. Drugs and the Pharmaceutical Sciences; vol 184.
  • Wright JC, Sekar M, van Osdol W, Su HC, Miksztal AR In situ forming systems (depots). In: Wright JC, Burgess DJ., eds. Long Acting Injections and Implants. New York, NY: Springer-Verlag; 2012:153-166. Advances in Delivery Science and Technology.
  • Sekar M, Okumo F, van Osdol W, Tamraz W, Tung D, Sverdrup F. SABER™ formulation for intra-articular delivery of rhGH. Poster session presented at: American Association of Pharmaceutical Scientists 2009 National Biotechnology Meeting; 2009 Jun 21-25.
  • Lee J, Jallo GI, Penno MB, et al. Intracranial drug-delivery scaffolds: biocompatibility evaluation of sucrose acetate isobutyrate gels. Toxicol Appl Pharmacol. 2006;215(1):64-70.
  • Betschart R, Fleury J, Squires EL, et al. Evaluation of the SABER™ delivery system for the controlled release of the GnRH analog deslorelin for advancing ovulation in mares: effect of gamma radiation. Poster session presented at: 25th International Meeting of the Controlled Release Society; 1998 Jun 21-26; Las Vegas, NV.
  • Fleury J, Squires EL, Betschart R, et al. Evaluation of the SABER™ delivery system for the controlled release of deslorelin for advancing ovulation in the mare: effects of formulation & dose. Poster session presented at: 25th International Meeting of the Controlled Release Society; 1998 June 21-26; Las Vegas, NV.
  • Burns P, Thompson D, Donadue F, et al. Pharmacodynamic evaluation of the SABER™ delivery system for the controlled release of the GnRH analogue deslorelin acetate for advancing ovulation in cyclic mares. Poster session presented at: 24th International Meeting of the Controlled Release Society; 1997 Jun 16-19; Stockholm, Sweden.
  • Donadue FJ, Thompson DL, Burns PJ, et al. Evaluation of the SABER™ delivery system for the release of GnRH analog deslorelin acetate for advancing ovulation in the mare. Poster session presented at: 15th Annual Meeting of the Equine Nutrition and Physiology Society Meeting; 1997 May 29-31; Fort Worth, TX.

 
SABER technology is also the basis for SucroMate™ Equine, a sustained-release injectable veterinary drug. SucroMate™ Equine was the first FDA-approved SABER product, launched in 2011 by our collaborator Thorn BioScience LLC, a division of CreoSalus, Inc.